September 24 is world heart day, and the eternal theme of world heart day is "healthy heart, happy life". It is well known that the heart is the only organ that cannot rest. Coronary heart disease, arrhythmia, heart failure, rheumatic, cardiomyopathy and other cardiovascular diseases a serious threat to human health, and high blood pressure, high cholesterol, high blood sugar is lead to stroke, myocardial infarction, and the main cause of peripheral vascular disease.
All over the world, about 17.5 million people die each year from heart disease, although the survivors of a heart attack and stroke every year at least 20 million, but most of them have caused by stroke sequela and the risk of disease recurrence. According to IMS data, the global drug market for cardiovascular systems reached us $89872 million in 2016, accounting for 8.9% of total drug use worldwide.
The cardiovascular disease in China report in 2016 showed that cardiovascular disease deaths accounted for the total urban and rural residents in 2015 the first cause of death, the number of patients with cardiovascular disease in our country has reached 290 million, each year about 2.6 million people die of cardiovascular disease, heart disease showed a trend of high incidence in our country.
The market of cardiovascular and cerebrovascular medicine is high concentration
CFDA south medicine published economic research institute, the development of Chinese pharmaceutical market blue book of 2017, according to a 2016 domestic cities, public hospitals, public hospitals at the county level, the urban community health care, in towns and townships, entity drug stores, shop three terminal 6 big market drug sales of 1.4975 trillion yuan, year-on-year growth of 8.3%. Among them, cardiac cerebrovascular, tumor immunity and infection class therapy drugs became the precurative category.
According to the data of HDM system of the southern institute of medicine and economics, the market for cardiovascular and cerebrovascular drugs in public hospitals in 16 key cities in China reached 17.812 billion yuan in 2016, up 6.19 percent from the previous year. This category covers heart attack drugs, brain vascular system drugs and anticoagulant antithrombotic drugs. Although the growth rate of cardiovascular and cerebrovascular market has slowed down in the past two years, the consumption of drug terminal has shown a trend of continuous increase. The data shows that the market size of China's cardiovascular systematized drugs, biological products and Chinese medicine has continued to grow, reaching 276.9 billion yuan in 2016, up 8.08% from the previous year.
FIG. 1 market of cardiovascular and cerebrovascular drugs in public hospitals in China's major cities from 2007 to 2016
In 2016, the total number of drugs in the TOP 20 varieties of cardiovascular and cerebral blood vessels in public hospitals in 16 key cities in China reached 13531 million yuan, accounting for more than 3/4 of the total amount of drugs, showing a high degree of product concentration. In 2016, the ranking of the TOP 20 types of cardio-cerebral vessels and the previous year also changed, and its varieties and growth trends were shown in FIG. 2, FIG. 3 and FIG. 4. The TOP 10 drug clopidogrel, lead to, atorvastatin, creatine phosphate and compound coenzyme, valsartan and compound, pursuant to the adr, low molecular heparin, statins, butyl phthalide rui shu.
Figure 2. The total market of Top 20 drugs in the heart of public hospitals in China's key cities from 2007 to 2016
FIG. 3 the market performance of heart cerebrovascular Top 10 in public hospitals in China's major cities from 2007 to 2016
Figure 4. Market performance of cardiac cerebrovascular No.11-20 in public hospitals in China's major cities from 2007 to 2016
Atorvastatin leads the fat market
The China cardiovascular disease report 2016, published by the national center for cardiovascular disease, is the 11th annual report released in China, which shows the high importance of the government's rise in cardiovascular disease. Universal positively with prevention and treatment of hypertension, dyslipidemia, diabetes and obesity syndrome, take positive and effective measures to curb increase cardiovascular disease has become the important of the era of large health project.
It has been more than half a century since the management of hypertension, and relatively speaking, effective management of hyperlipidemia has been a civil action for more than a decade. Statins are a milestone in lowering cholesterol and blood lipids.
At present, fall hematic fat market statins are: atorvastatin, rui shu cut statin, horse cutting statin, simvastatin, pravastatin, fluorine cut statin, lovastatin, and compound preparations simvastatin + o in accordance with the folding mab, cutting statin + amlodipine, lovastatin + nicotinic acid and so on more than 10 varieties.
Atorvastatin is the number one drug in the market for blood lipids, and the top three drugs in the cardiovascular market. Chinese medical information system CMH data show that atorvastatin is growing rapidly. In 2016, the sales volume of atorvastatin, a public hospital in China, was 60.75 billion yuan, while the market of atorvastatin, a domestic retail pharmacy, reached 24.31 billion yuan, and the two main mainstream terminals reached 8.506 million yuan. Domestic urban public hospitals, county-level public hospitals, urban community health clinics, township hospitals, physical pharmacies, and online shopping centers of the three major terminals, atorvastatin sales have exceeded 13 billion yuan.
In 2016, according to HDM system data key cities public hospital atorvastatin, rui shu cut statin, horse cutting cholesterol-lowering statin is TOP 3 drugs market, year-on-year growth of 8.78% last year, 8.78% and 10.91% respectively, three terminal 6 big domestic market reached 23.827 billion yuan, up to 25 billion yuan in 2017.
Clopidogrel was the top drug market
Cardiovascular system drugs bei song class (Betrixaban), is in the first half of 2017 wave tora (Portola) companies are allowed to listed in the U.S. and an oral factor Xa inhibitors class anticoagulants, is cutting shaaban, pp shaaban, according to the degree of the sand after class global listings fourth, mechanism of action of the same drug is the advantage of bei song shaaban can be used as the replacement therapy of warfarin sodium, anticoagulant therapy for atrial fibrillation provides a new choice.
In the field of atrial fibrillation anticoagulant therapy, antithrombotic and anticoagulant markets have been further improved with the entry of rivaroxaban, apperchaban, darbika group esters, tigliello and pragrel into clinical practice. However, the species of clopidogrel and low molecular heparin in the Chinese market still play an inestimable role.
In the late 1990 s, the FDA approved the bristol-myers squibb (BMS) research and development of clopidogrel, used for the prevention and treatment of atherosclerosis disease, myocardial infarction, stroke, and peripheral vascular disease and other diseases, become a variety of cardiovascular medicine milestone field type.
Clopidogrel and the small dose of aspirin are known as anti-platelet aggregation, the gold standard treatment for thrombosis, and a drug to prevent heart attacks and stroke in the treatment of hypertension. Clopidogrel was co-sold by bristol-myers squibb and sanofi-aventis, which is called Plavix. Clopidogrel is one of the earliest listed products in China. Currently, 16 clopidogrel production lines have been built in China. In 2000, China first approved the registration of clopidogrel in shenzhen xinlitai pharmaceutical co., which is called "tijia".
Sanofi's clopidogrel was listed in our country as "bolivy", which was promoted by the original drug and domestic medicine, and clopidogrel was a fast-growing breed. During the period from 2005 to 2015, the compound annual growth rate was 29.8%. After the market developed to the platform stage, the growth rate slowed down in the near three years, and the dosage continued to rise.
According to the data of HDM system, the market of clopidogray, a public hospital in 16 key cities in China, was 1.529 billion yuan in 2016, up 6.25% from the previous year. Among them, sanofi-aventis's pollivy occupies 58.84 percent, while the taijia of shenzhen xinlitai occupies 35.27 percent and the yuepu pharmaceutical company occupies 5.89 percent. The growth rate of boli and tijia is 5.24% and 3.66%, while the growth rate of yuk is up to 40.30%. In 2016, the total sales volume of clopidogrel in China exceeded 10 billion yuan, which was the first drug in the domestic heart drug market.
Figure 5. The market of clopidogrel, a public hospital of key cities in China from 2007 to 2016
7 antihypertensive drugs are in the Top 20
Calcium antagonists, renin-angiotensin receptor antagonists and beta blockers are three of the most powerful drugs in China's anti-hypertensive market. Its mechanism is not only the control of blood pressure, heart, brain and kidney in patients with high blood pressure also important organs such as protective, clinical treatment of coronary heart disease, heart failure, arrhythmia, protect kidney function and reverse left ventricular hypertrophy and vascular remodeling, etc have a positive effect.
According to the CMH data, the market size of antihypertensive drugs in urban public hospitals in China was 36.6 billion yuan in 2016, up 13 percent year on year. Under the medical security system is increasingly perfect, market pattern, according to the TOP 5 category accounted for 34%, calcium antagonists renin - angiotensin receptor antagonist (28%), beta blockers accounted for 8%, compound preparations (7%), diuretics (2%); Other 21 percent.
Key city public hospital cardiovascular drugs market TOP 20 varieties, antihypertensive drug amlodipine, left amlodipine, nifedipine and valsartan and compound, er bei sha Tanzania and compound, and compound chlorine sand, metoprolol and other seven drugs account for 21.40%.
FIG. 6 market performance of the blood pressure drug in the heart cerebral blood vessel Top 20 of public hospitals in China's major cities from 2007 to 2016
HDM system, according to data from 2016 key cities public hospital calcium antagonists of amlodipine and nifedipine, amlodipine left the sum of 484 million yuan, 378 million yuan and 281 million yuan respectively, than the previous year increased by 0.16%, 0.16% and 0.16% respectively; Renin - angiotensin receptor antagonist valsartan series, series he sand, chlorine sand jotham series sum of 696 million yuan, 397 million yuan and 382 million yuan respectively, than the previous year increased by 1.57%, 0.16% and 1.57% respectively. As a group of anti-hypertensive new drugs enter medicare, the market will be driven directly.
|
